In clinical trials of liraglutide for weight management, weight loss was seen at 1.2, 1.8, 2.4, and 3 mg doses. The 3 mg dose was the most effective dose; 76% of participants lost more than 5% of their body weight after 20 weeks. Liraglutide was also more effective than orlistat (Alli, Xenical).
Read more about liraglutide weight management clinical trials (SCALE Studies):
Saxenda 3 mg daily was compared with placebo in a 56-week study consisting of obese or overweight patients with risk factors such as hypertension or dyslipidemia. The average weight was 106.2 kg in both groups. The change in weight from baseline was -7.45 for Saxenda and -3.0% for placebo. 62.3% of subjects treated with Saxenda and 34.4% of subjects in the placebo group lost 5% or more of their body weight.
In a similar study consisting of obese or overweight patients with type 2 diabetes the change in weight from baseline was -5.4% in the Saxenda group and -1.7% in the placebo group. 49% of subjects treated with Saxenda and 16.4% of subjects in the placebo group lost 5% or more of their body weight.
The recommended dose of Saxenda is 3 mg daily injected in the abdomen, thigh or upper arm. Treatment should be initiated at 0.6 mg per day and the dose should be increased by weekly intervals until a daily dose of 3 mg is reached. Saxenda treatment should be evaluated after 16 weeks to determine its effectiveness. Saxenda should be discontinued if at least 4% of baseline body weight is not lost by week 16 weeks because continued treatment is not likely to yield significant weight loss.
Saxenda is not approved for treatment of type 2 diabetes and should not be combined with other GLP-1 receptor agonists such as Victoza, Byetta, and Bydureon. In clinical trials the most common side effects of Saxenda were nausea, hypoglycemia, diarrhea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, and increased lipase.